AI Summary & Key Takeaways
AI InsightOverall survival (OS) was significantly better in patientswith comparatively lower N, M0, low stage, and peripheral location.CONCLUSION: This study demonstrated a single-center experience with clinicopathologic factors and survival outcomes of LCNECpatients.
📌 3 Key Takeaways
Özet
OBJECTIVES: Neuroendocrine tumors of the lungs are a clearly different group of tumors with definite ultrastructural, immunohistochemical, and molecular features. We reported and analyzed the incidence, clinicopathological features, surgery rates, responses to first-linetherapy, and survival outcomes of this rare condition according to our lung cancer patient database.MATERIALS AND METHODS: We retrospectively collected the data of 62 patients who were histopathologically diagnosed with largecell neuroendocrine carcinoma of lung (LCNEC) between January 2010 and January 2016.RESULTS: The patients were predominantly (95%) men (male:female=59:3) with their average age being 60.3±8.6 years. Diagnosis wasmade by the fine-needle aspiration biopsy (NAB) in 7 patients, bronchoscopic transbronchial biopsy in 13, and surgery in 42. Nearly43.5% of the patients presented with the tumor in the right upper lobe. Additionally, tumors of 46.8% patients could be observed in peripheral locations. Sixteen patients presented with stage 1, 17 with stage 2, 15 with stage 3, and 14 with stage 4. Median progression-freesurvival (PFS) was 29 months (SE: 12.2) (95% CI, 5.2–52.8 months). Progression-free survival (PFS) was significantly better in patients withlow N, M0, early stage, p63 positive, and TTF-1 positive across the entire cohort. Overall survival (OS) was significantly better in patientswith comparatively lower N, M0, low stage, and peripheral location.CONCLUSION: This study demonstrated a single-center experience with clinicopathologic factors and survival outcomes of LCNECpatients.